- Company
- Dupixent sales skyrocket with 'expanded indications'
- by Son, Hyung Min Oct 30, 2024 05:54am
- Sales for 'Dupixent,' a biological agent developed by Sanofi, continue to skyrocket. Net sales for Dupixent from Q1 to Q3 of 2024 reached 10 billion euros. The analysis suggests that Dupixent's added indications to treat various immune diseases, including atopic dermatitis, asthma, esophagitis, and chronic obstructive pulmonary disease (COPD), h
- Company
- "Early intervention" needed for treating multiple myeloma
- by Whang, byung-woo Oct 29, 2024 05:49am
- The survival rate of patients with multiple myeloma increased following new drug development. However, concerns have been raised that South Korea's survival rate is still far from that of advanced countries. Expert opinions indicate that the Korean medical treatment field changes with new drug approvals and reimbursement listings, yet patien
- Company
- Will the third time be the charm for Mylotarg?
- by Eo, Yun-Ho Oct 29, 2024 05:49am
- The industry’s attention is focused on whether the insurance reimbursement discussions for the acute myeloid leukemia drug ‘Mylotarg’ will make progress this time. According to the industry sources, Pfizer Korea’s acute myeloid leukemia (AML) drug ‘Mylotarg (gemtuzumab ozogamicin)’ is set to be submitted to the Health Insurance Revi
- Company
- ABL Bio receives ₩7B as milestone payment from Sanofi
- by Kim, Jin-Gu Oct 29, 2024 05:49am
- ABL Bio has received additional milestone payments from Sanofi for its degenerative brain disease treatment candidate ‘ABL301’. Including the upfront payment., ABL Bio will receive a total of KRW 170 billion, which includes the upfront payment. On 28 February, ABL Bio announced the completion of the manufacturing technology transfer o
- Company
- 'Aquipta,' new oral migraine drug, can be prescribed
- by Eo, Yun-Ho Oct 28, 2024 05:53am
- AbbVie Korea's new drug 'Aquipta,' an oral drug used to treat migranes, is expanding the number of hospitals where it can be prescribed. According to industry sources, Aquipta (atogepant), an oral calcitonin gene-related peptide (GRRP) receptor antagonist for migraine treatment, has passed the drug committee (DC) of tertiary general hosp
- Company
- Will Roche’s lymphoma drug Columvi be discussed for reimb?
- by Eo, Yun-Ho Oct 28, 2024 05:53am
- Will Columvi, the first bispecific antibody treatment option for lymphoma, enter the first step to its reimbursement within the year? Roche Korea’s CD20-CD3 bispecific antibody for diffuse large B-cell lymphoma (DLBCL), Columvi (glofitamab), may likely be redeliberated by the Health Insurance Review and Assessment Service's Cancer Diseas
- Company
- "We have clinically proven Stelara for Koreans"
- by Moon, sung-ho Oct 28, 2024 05:53am
- Due to its wide variety of conditions, Crohn's disease requires customized long-term treatment depending on the disease type and inflammatory region. When treating patients with Crohn's disease, the location of the disease is challenging because the intestinal tract of the ileum (lower part of the small intestine) is narrow. Recently, the re
- Company
- Januvia generics occupy 17% of market in 1yr
- by Kim, Jin-Gu Oct 28, 2024 05:53am
- Generic versions of the DPP-4 inhibitor diabetes drug ‘Januvia (sitagliptin)’ have expanded their share to 17% within a year of its launch. In the pharmaceutical industry, the assessment is that their penetration rate is somewhat slower compared to other DPP-4 inhibitor generics. In fact, the generic versions of Galvus (vildagliptin
- Company
- Will the ATTR-CM drug 'Vyndamax' receive reimb approval?
- by Eo, Yun-Ho Oct 25, 2024 05:49am
- Will 'Vyndamax,' a new drug used to treat transthyretin amyloid cardiomyopathy, successfully be listed for insurance reimbursement? Pfizer Korea's Vyndamax (tafamidis 61 mg), a treatment for ATTR-CM (ATTR amyloidosis with cardiomyopathy), has recently passed the Drug Reimbursement Evaluation Committee (DREC) of the Health Insurance Review
- Company
- K-new drugs Rosuzet·K-CAB dominate the prescription market
- by Chon, Seung-Hyun Oct 25, 2024 05:48am
- Pharmaceuticals developed by Korean pharmaceutical companies using their R&D capacities have strengthened their influence on the outpatient prescription market. Quarterly prescription sales of Hanmi Pharmaceutical's new combination drug, Rosuzet, and HK inno.N's K-CAB exceeded KRW 50 billion, ranking at the top. Astra Zeneca's anticancer agent,
